OMGA (omegatherapeutics.com) Company Net Income

Corporate emblem and logo of Omega Therapeutics Inc (OMGA)

The profitability of Omega Therapeutics (OMGA) helps assess its resilience to geopolitical risks and raw material supply disruptions. Current growth is supported by the creation of innovative gene expression management methods for tissue regeneration. The strategy is based on epigenetic reprogramming without DNA editing to combat cancer. The value of 0.00 captures the current state of the parameter, demonstrating the expansion dynamics of the issuer's operating margin.

OMGA Omega: Net Profit in the range 07/04/2022 - 03/08/2025

Comprehensive metric breakdowns and analytics for Omega Therapeutics, Inc. (OMGA)

- price and consensus price forecast:
Stock Quotes Omega Therapeutics Corp|OMGA - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Omega Therapeutics Corp|OMGA - Enterprise Value
- balance sheet equity data:
Book Value of One Share Omega Therapeutics|OMGA - Book Capitalization|Market Capitalization to Book Value Ratio omegatherapeutics.com|OMGA - Cumulative Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Omega Therapeutics|OMGA - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Omega Therapeutics Inc|OMGA - Company Aggregate Debts|Debt to Net Assets Ratio Omega Therapeutics Corp|OMGA - Company Long-Term Debts|Short-Term Debt Omega Therapeutics|Intermediate Coverage Ratio omegatherapeutics.com
- business earnings and investment ratios data:
OMGA - Net Profit
Fundamental valuation:Omega Therapeutics Corp (OMGA)
Manufactured products of omegatherapeutics.com

This indicator reflects the daily equity value of the business by allocating quarterly net income across calendar days to provide an objective assessment of fundamental dynamics. For Omega Therapeutics (OMGA), this profit history visualizes the monetization of genetic engineering patents and partnership payments, where the upward trend confirms the capitalization of intellectual property and the overall financial stability of the issuer.

Direct competitors

Net Income Tempus AI|QGEN (Qiagen N.V.) - Net Profit|Company Net Income ionispharma.com IONS|Net Profit RGEN|Avidity Biosciences Inc (RNA) - Annual Net Income|Net Profit CRSP (CRISPR Therapeutics Corp)|Net Profit GeneDx Corp WGS|RARE: Net Income|Final Profit BEAM (beamtx.com)|SRPT (Sarepta) - Net Income|TWST: Profit After Payment of Taxes|TXG (10x Genomics Corp) - Net Profit|NTLA: Final Profit|Net Profit STOK|BLFS - Company Net Income|Company Net Income Wave Life Sciences Ltd. WVE|Final Profit MAZE|Sionna Pharma - Net Profit|PRME - Net Profit|Taysha Gene Therapies (TSHA) - Company Net Income|Profit After Tax QURE (uniqure.com)|MGTX (MeiraGTx) - Net Profit|Company Net Income REGENXBIO Inc RGNX|Net Income SLDB (Solid Bio)|Net Profit Ocugen Pharma (OCGN)|Pacific Biosciences - Net Income|Profit After Payment of Taxes BNTC (benitec.com)|Design Therapeutics, Inc. - Net Profit|Net Financial Result Rocket Pharma RCKT|FDMT: Net Profit|Net Income Lexeo Therapeutics, Inc.|Company Net Income Korro Bio Inc.|editasmedicine.com (EDIT) - Net Financial Result|Company Net Income Silence Therapeutics plc (SLN)|PRQR - Company Net Income|Company Net Income Codexis CDXS|SGMO - Net Income|Nautilus Biotechnology Inc - Net Profit|Annual Net Income metagenomi.co (MGX)|DTIL: Net Profit|Generation Bio (GBIO) - Net Profit|BOLD (Boundless Bio, Inc) - Net Profit|Company Profit XCUR (Exicure Corp)|Company Net Income Imunon, Inc. (IMNN)|phiopharma.com - Company Profit|Net Profit MBIO (Mustang Bio)|Net Profit TransCode Therapeutics Inc. RNAZ|BNGO - Company Net Income|Company Net Income Applied DNA Corp|bluebird bio, Inc. (BLUE) - Company Net Income|Net Income ImmunoPrecise Antibodies Ltd.|OMIC (Singular Genomics) - Net Profit|Company Net Income Regulus Therapeutics, Inc. RGLS|Net Profit SYRS|Telesis Bio, Inc (TBIO) - Annual Net Income|Net Profit TCON (TRACON Pharmaceuticals)|Net Profit unitybiotechnology.com UBX